RESUMO
The purpose of this study was to determine the stability of oseltamivir, the active ingredient in Tamiflu, in contemporaneously compounded suspensions for a period of not less than 90 days. The suspension vehicles provided for the study were chosen because of ease of preparation, commercial availability, and palatability. Stability of the active ingredient was demonstrated for suspensions prepared in PCCA-Plus, PCCA Acacia, and 1% methylcellulose and was independent of storage temperature (tested temperatures were 2 deg C to 8 deg C and 25 deg C). A control sample of the commercial liquid form of Tamiflu was prepared, stored and analyzed along with the samples prepared from the contents of capsules. There was no difference in the apparent stability of the two forms of the drug preparation.